Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE – Get Free Report) have earned a consensus recommendation of “Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.3333.
NAGE has been the subject of several research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Friday, July 17th. Freedom Capital upgraded Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday. Canaccord Genuity Group reduced their price objective on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th.
Read Our Latest Analysis on Niagen Bioscience
Niagen Bioscience Price Performance
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%.The firm had revenue of $29.78 million during the quarter, compared to the consensus estimate of $29.95 million. As a group, sell-side analysts anticipate that Niagen Bioscience will post 0.21 EPS for the current fiscal year.
Institutional Investors Weigh In On Niagen Bioscience
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. purchased a new stake in Niagen Bioscience during the 3rd quarter valued at approximately $37,522,000. SteelPeak Wealth LLC purchased a new stake in shares of Niagen Bioscience during the first quarter worth approximately $14,875,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after purchasing an additional 761,685 shares during the last quarter. UBS Group AG lifted its holdings in shares of Niagen Bioscience by 18.0% during the fourth quarter. UBS Group AG now owns 1,411,742 shares of the company’s stock worth $8,979,000 after purchasing an additional 215,645 shares during the period. Finally, Renaissance Technologies LLC grew its position in Niagen Bioscience by 45.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after buying an additional 414,725 shares during the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Featured Stories
- Five stocks we like better than Niagen Bioscience
- Is ADM’s Rally Getting Ahead of Its Policy Tailwind?
- CoreWeave Powers Up: The Asia Infrastructure Grab
- Boot Barn Stock Still Has Room to Run, But It Must Earn Its Premium
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
